Skip to content

Elevance Health ELV Proceeds from issuance of commercial paper and other short-term borrowings

Proceeds from issuance of commercial paper and other short-term borrowings at other companies

Humana logo
HumanaHUM

Other financials

Income statement

See full
Revenue$50.2B+2.6%
Gross profit$44.7B+1.8%
Net income$1.8B-19.2%
EPS (diluted)$8.00-16.8%

Balance sheet

See full
Cash & equivalents$9.7B+28.8%
Total debt$31.5B+11.0%
Total equity$43.9B+3.3%
Total assets$125.83B+5.1%

Cash flow

See full
Operating cash flow$4.3B+326%
CapEx$235.0M+19.9%
Free cash flow$4.1B+399%

Valuation

See full
Market cap$83.98B+7.6%
Enterprise value$105.82B+8.0%
P/E16×+1.5×
P/S0.4×0.0×

Profitability

See full
Gross margin89.2%+0.6pp
Net margin2.6%-0.6pp
FCF margin3.3%+1.3pp

Returns & leverage

See full
Return on equity12.1%-2.1pp
Debt / equity0.7×+0.1×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Elevance Health in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromShortTermDebt.

The official record: Elevance Health’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Elevance Health's proceeds from issuance of commercial paper and other short-term borrowings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Elevance Health's proceeds from issuance of commercial paper and other short-term borrowings?
Elevance Health (ELV) reported proceeds from issuance of commercial paper and other short-term borrowings of $724M in Q1 2026.
What does proceeds from issuance of commercial paper and other short-term borrowings mean?
This represents cash inflows from borrowing arrangements with maturities of one year or less, such as commercial paper or revolving credit lines. It is used to manage short-term liquidity and working capital needs.